DRUG Healthcare

Bright Minds Biosciences Inc.

$21.55-17.75%

Price as of close on Nov 3, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 212.6M USD
Enterprise value: -8.1M USD
Full-time employees: 26

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
Bright Minds Biosciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Bright Minds Biosciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Bright Minds Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to September 2025.
Bright Minds Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 13 months ago.
The latest financial period we have ended 13 months ago, so the scores may not reflect recent results.

StockQuotient Score

—

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-1.0%

SEC filings (IFRS mapped) · 12 months to Sep 2025 · CAD→USD at the current rateNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-8.3%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · CAD→USD converted · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield6.4%

SEC filings (IFRS mapped) · latest balance sheet · CAD→USD at the current rateReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 100 → 98

Company's reported figures updated+98
Peer companies moved-100

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity
▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.20

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.24Sector median: 0.6250 · MAD: 0.3380

Current ratio36.10×

SEC filings (IFRS mapped) · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Bright Minds Biosciences

Is Bright Minds Biosciences getting weaker?: Its latest SEC filing (Dec 23, 2025) showed no major changes.
How is Bright Minds Biosciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -1.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.0% vs peers 1.5% (weaker than 100% of peers).
Is Bright Minds Biosciences growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Bright Minds Biosciences?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Bright Minds Biosciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 36.10× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 36.10× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Sep 30, 2025 · filed Dec 23, 2025 · compared with the year ended Sep 30, 2024

No major changes

	Previous year	Latest year	Change
Net income (12 months)	−2.8M CAD	−12.2M CAD	+336.5%
Cash	5.7M CAD	82.9M CAD	+1349.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in CAD, as reported

Key ratios	FY Sep 2021	FY Sep 2022	FY Sep 2023	FY Sep 2024	FY Sep 2025	Change
Return on assets (ROA)	-43.2%	-123.8%	-107.2%	-45.9%	-14.5%	▲ 31 pts
Return on equity (ROE)	-44.6%	-141.9%	-111.7%	-50.6%	-14.9%	▲ 36 pts
Current ratio	31.38×	8.11×	24.26×	11.32×	36.10×	▲ 219%

DRUG price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

Bright Minds Biosciences's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Bright Minds Biosciences's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Bright Minds Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to September 2025.

Bright Minds Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 13 months ago.

The latest financial period we have ended 13 months ago, so the scores may not reflect recent results.

Questions investors ask about Bright Minds Biosciences

Is Bright Minds Biosciences getting weaker?

Its latest SEC filing (Dec 23, 2025) showed no major changes.

How is Bright Minds Biosciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -1.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.0% vs peers 1.5% (weaker than 100% of peers).

Is Bright Minds Biosciences growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Bright Minds Biosciences?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Bright Minds Biosciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 36.10× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 36.10× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Net income (12 months)

−2.8M CAD

−12.2M CAD

+336.5%

Cash

5.7M CAD

82.9M CAD

+1349.4%

Key ratios

FY Sep 2021

FY Sep 2022

FY Sep 2023

FY Sep 2024

FY Sep 2025

Change

Return on assets (ROA)

-43.2%

-123.8%

-107.2%

-45.9%

-14.5%

▲ 31 pts

Return on equity (ROE)

-44.6%

-141.9%

-111.7%

-50.6%

-14.9%

▲ 36 pts

Current ratio

31.38×

8.11×

24.26×

11.32×

36.10×

▲ 219%